Ypsomed Holding AG (LON: 0QLQ)
London
· Delayed Price · Currency is GBP · Price in CHF
357.00
-9.00 (-2.46%)
Jan 23, 2025, 1:43 PM BST
Ypsomed Holding AG Revenue
Ypsomed Holding AG had revenue of 324.01M CHF in the half year ending September 30, 2024, with 32.66% growth. This brings the company's revenue in the last twelve months to 617.07M, up 21.33% year-over-year. In the fiscal year ending March 31, 2024, Ypsomed Holding AG had annual revenue of 548.46M with 10.25% growth.
Revenue (ttm)
617.07M CHF
Revenue Growth
+21.33%
P/S Ratio
n/a
Revenue / Employee
268.76K CHF
Employees
2,296
Market Cap
4.44B GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 548.46M | 51.00M | 10.25% |
Mar 31, 2023 | 497.46M | 32.62M | 7.02% |
Mar 31, 2022 | 464.84M | 61.19M | 15.16% |
Mar 31, 2021 | 403.66M | 9.39M | 2.38% |
Mar 31, 2020 | 394.26M | -59.50M | -13.11% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |